GENEVA, SWITZERLAND--(Marketwired - January 12, 2015) - Etrion Corporation ("Etrion" or the "Company") (TSX: ETX) (OMX: ETX), a solar independent power producer, announces that the Company's CEO, Marco A.
Fourth Quarter Revenue Increases 11.3% to $92.8 Million Full Year 2014 Revenue of $345.4 Million Represents 11.1% Growth Fourth Quarter Extremities Revenue Grew 16.0% in Constant Currency Over Prior Year
AMSTERDAM, The Netherlands, Jan.
Sign-up for - DBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of Allergy investment picks
Hospitality Properties Trust (NYSE: HPT) today announced a regular
quarterly common share distribution of $0.49 per common share ($1.96 per
share per year). This distribution will be paid to HPT’s common
shareholders of record as of the close of business on January 23, 2015
and distributed on or about February 24, 2015.
To better enable the mobile workforce, Accenture (NYSE:ACN) has made its Accenture
CAS software available on Windows 8.1 devices, starting with tablets
and followed by mobile phones, providing clients with access to a single
platform that spans sales processes and operations for integrated and
efficient management – all from their mobile devices.
GameStop (NYSE:GME), a family of specialty retail brands that makes the
most popular technologies affordable and simple continues to expand its
roster of technology companies and institutions it is collaborating with
as part of its GameStop Technology Institute (GTI) business unit.
NEWARK, CA--(Marketwired - January 12, 2015) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) today announced positive preliminary results from its clinical study of arhalofenate administered in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). Arhalofenate is a once-daily, oral candidate for the treatment of gout with a unique dual mechanism of action which lowers serum uric acid (sUA) while also reducing the occurrence of gout flares.
Exelon today issued the following statement on the State of Illinois
report on potential nuclear power plant closings prepared in response to
House Resolution 1146:
We thank the state for its attention and work on such an important issue
for Illinois and the future of the state’s energy assets.
Wayfair Inc. (NYSE:W), one of the world’s largest online destinations
for home furnishings and decor, announced today that Niraj Shah, CEO,
co-founder, and co-chairman will present at the ICR XChange Conference
held at the JW Marriott Orlando Grande Lakes in Orlando, Florida on
Tuesday, January 13 at 1 p.m. Eastern Time.
GE Antares, a unit of GE Capital, announced today it closed more than
200 senior loan transactions with corporate borrowers across 88 private
equity firms, including 62 new platforms, totaling more than $27 billion
in financing in 2014, making it the most active lender to private
equity-backed companies in the middle market.
First Trust Dividend and Income Fund (the “Fund”) (NYSE: FAV) today
declared its regularly scheduled quarterly distribution payable on
January 30, 2015, to shareholders of record as of January 26, 2015.
Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced
that the U.S. Federal Trade Commission (FTC) has granted early
termination of the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976 (HSR Act) with respect to Actavis’ pending
acquisition of Allergan.
Sign-up for - Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings investment picks
By Don Clark
Advanced Micro Devices Inc. said three senior executives are leaving the chip maker, the latest sign that Chief Executive Lisa Su is revamping the organization to help find new revenue growth.
Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers
Squibb Company (NYSE:BMY) today announced that the companies have
entered into a clinical trial collaboration agreement to evaluate the
investigational combination of Seattle Genetics’ antibody-drug conjugate
(ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s
immunotherapy Opdivo (nivolumab) in two planned Phase 1/2
Sign-up for - Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.